Inhibikase Therapeutics (IKT) Accumulated Expenses (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Accumulated Expenses data on file, last reported at $4.1 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $4.1 million, up 101.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.1 million (up 101.67% YoY), and the FY2025 annual result was $581761.0, down 78.29% from the prior year.
• Accumulated Expenses grew to $4.1 million in Q1 2026 per IKT's latest filing, from $581761.0 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $4.1 million in Q1 2026 and troughed at $417573.0 in Q3 2022.
• A 5-year average of $1.9 million and a median of $2.0 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses jumped 3461.93% in 2022, then plunged 78.29% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $459997.0 in 2022, then surged by 391.3% to $2.3 million in 2023, then rose by 18.59% to $2.7 million in 2024, then sank by 78.29% to $581761.0 in 2025, then soared by 608.99% to $4.1 million in 2026.
• Business Quant data shows IKT's Accumulated Expenses at $4.1 million in Q1 2026, $581761.0 in Q4 2025, and $2.1 million in Q3 2025.